Comprehensive Molecular Tumor Analysis (CMTA) integrating RNAseq and TME for targeted therapy

On Demand

55mins

Share webinar

55mins

Alacris Theranostics' Comprehensive Molecular Tumor Analysis (CMTA) uses whole exome and transcriptome sequencing with MGI DNBSEQ technology. It's beneficial for guiding targeted therapies in complex or unknown tumors, enhancing personalized cancer treatment plans.

Dr. Marie-Laure Yaspo - Co-founder and Chief Scientific Officer @ Alacris Theranostics GmbH

Dr. Marie-Laure Yaspo - Co-founder and Chief Scientific Officer @ Alacris Theranostics GmbH

Priyanka Kurapati - Field Application Scientist @ MGI-tech

Priyanka Kurapati - Field Application Scientist @ MGI-tech

pagination here
pagination here
Genomics Unlocked Background

Join our newsletter to stay up to date on our latest webinars.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Genomics Unlocked Background

Join our newsletter to stay up to date on our latest webinars.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Genomics Unlocked Background

Join our newsletter to stay up to date on our latest webinars.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.